OnKure Therapeutics (OKUR) Competitors $2.54 -0.06 (-2.31%) Closing price 04:00 PM EasternExtended Trading$2.54 0.00 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKUR vs. CTOR, KALA, ONCY, CRDF, LFVN, TIL, HURA, ACOG, ZURA, and IKTShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Citius Oncology (CTOR), KALA BIO (KALA), Oncolytics Biotech (ONCY), Cardiff Oncology (CRDF), Lifevantage (LFVN), Instil Bio (TIL), TuHURA Biosciences (HURA), Alpha Cognition (ACOG), Zura Bio (ZURA), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors Citius Oncology KALA BIO Oncolytics Biotech Cardiff Oncology Lifevantage Instil Bio TuHURA Biosciences Alpha Cognition Zura Bio Inhibikase Therapeutics OnKure Therapeutics (NASDAQ:OKUR) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Is OKUR or CTOR more profitable? Citius Oncology's return on equity of -51.93% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -60.52% -55.43% Citius Oncology N/A -51.93%-22.17% Which has more risk & volatility, OKUR or CTOR? OnKure Therapeutics has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 2.99, suggesting that its stock price is 199% more volatile than the S&P 500. Does the media prefer OKUR or CTOR? In the previous week, Citius Oncology had 5 more articles in the media than OnKure Therapeutics. MarketBeat recorded 8 mentions for Citius Oncology and 3 mentions for OnKure Therapeutics. Citius Oncology's average media sentiment score of 0.56 beat OnKure Therapeutics' score of -0.03 indicating that Citius Oncology is being referred to more favorably in the news media. Company Overall Sentiment OnKure Therapeutics Neutral Citius Oncology Positive Do institutionals and insiders have more ownership in OKUR or CTOR? 91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 2.3% of OnKure Therapeutics shares are owned by insiders. Comparatively, 4.6% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, OKUR or CTOR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.53Citius OncologyN/AN/AN/AN/AN/A Do analysts prefer OKUR or CTOR? OnKure Therapeutics presently has a consensus target price of $32.33, indicating a potential upside of 1,172.97%. Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 229.67%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe OnKure Therapeutics is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.14Citius Oncology 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCitius Oncology beats OnKure Therapeutics on 6 of the 11 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.37M$3.07B$5.65B$10.29BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-0.5320.7975.8626.14Price / SalesN/A404.26515.95170.63Price / CashN/A45.9137.5661.52Price / Book0.339.6312.886.30Net Income-$52.67M-$52.73M$3.29B$271.03M7 Day Performance2.42%0.66%-0.24%-0.13%1 Month Performance-9.93%6.33%3.87%6.43%1 Year PerformanceN/A18.99%68.39%28.82% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics2.8125 of 5 stars$2.54-2.3%$32.33+1,173.0%N/A$34.37MN/A-0.53N/AGap UpCTORCitius Oncology2.4887 of 5 stars$1.78+1.1%$6.00+237.1%+7.7%$137.93MN/A0.00N/AAnalyst UpgradeGap UpKALAKALA BIO4.1784 of 5 stars$18.55-5.5%$27.50+48.2%+246.7%$137.82M$3.89M-2.7330Gap UpONCYOncolytics Biotech2.4391 of 5 stars$1.30-4.4%$5.00+284.6%+38.9%$136.49MN/A-4.8130CRDFCardiff Oncology2.3268 of 5 stars$2.07+1.0%$10.63+413.3%-21.0%$136.38M$680K-2.3820Positive NewsLFVNLifevantage3.974 of 5 stars$10.55-0.8%$30.50+189.1%-5.5%$134.90M$228.53M14.26260High Trading VolumeTILInstil Bio3.2845 of 5 stars$19.37-2.8%$88.50+356.9%-74.3%$134.54MN/A-1.50410Positive NewsGap DownHURATuHURA Biosciences1.5397 of 5 stars$2.55-2.3%$12.67+396.7%N/A$130.62MN/A0.00N/AACOGAlpha Cognition2.7344 of 5 stars$8.00-0.2%$20.00+150.0%N/A$129.61MN/A-5.00N/APositive NewsGap UpZURAZura Bio3.7733 of 5 stars$2.11+6.0%$11.60+449.8%-42.8%$129.39MN/A-3.013Positive NewsIKTInhibikase Therapeutics1.6533 of 5 stars$1.68+2.4%$6.50+286.9%+49.6%$125.19MN/A-0.636News Coverage Related Companies and Tools Related Companies Citius Oncology Alternatives KALA BIO Alternatives Oncolytics Biotech Alternatives Cardiff Oncology Alternatives Lifevantage Alternatives Instil Bio Alternatives TuHURA Biosciences Alternatives Alpha Cognition Alternatives Zura Bio Alternatives Inhibikase Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OKUR Stock Alerts